Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram vs Nortriptyline for Relapse Prevention after ECT (DUAG-7)
NCT00660062Phase 4Terminated
- Sponsor
- Nordsjællands Hospital
- Start
- Aug 2009
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of escitalopram in major depressive disorder (MDD), sponsored by Nordsjællands Hospital. Primary endpoint: Hamilton Depression Rating Scale at 14 days. Started Aug 2009; status: terminated.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00660062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00660062.